Skip to main content
Climb Bio, Inc. logo

Climb Bio, Inc. — Investor Relations & Filings

Ticker · CLYM ISIN · US28658R1068 US Professional, scientific and technical activities
Open in API
Filings indexed 276 across all filing types
Latest filing 2026-06-09 Regulatory Filings
Country US United States of America
Listing US CLYM

About Climb Bio, Inc.

https://climbbio.com/

Climb Bio, Inc. is a clinical-stage biotechnology company that develops therapeutics for patients with immune-mediated diseases. The company's mission is to deliver high-impact, disease-modifying medicines, with a scientific approach centered on developing differentiated monoclonal antibodies. Its pipeline includes investigational therapies for diseases with limited therapeutic options, which are being advanced through clinical studies across multiple areas to evaluate their potential to improve patient outcomes.

Recent filings

Filing Released Lang Actions
424B3
Regulatory Filings Classification · 85% confidence The document is a Securities and Exchange Commission prospectus filed pursuant to Rule 424(b)(3) registering resale of common stock by selling stockholders. It is an offering/prospectus rather than a financial report, earnings release, board management change, or other specific category. It does not contain substantive financial statements or management discussion, nor is it a proxy, dividend notice, or M&A filing. It is best classified as a general regulatory filing under our fallback category for miscellaneous disclosures (RNS).
2026-06-09 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a Current Report on Form 8-K, primarily disclosing the results of stockholder votes on corporate matters at the 2026 Annual Meeting—including director elections, auditor ratification, charter amendment vote, and equity plan amendment. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA), which covers official reporting of shareholder vote outcomes at general meetings.
2026-06-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act, with an Item 8.01 “Other Events” announcement of clinical data. It does not contain full financial statements, nor is it an earnings release, management change, proxy, or other specific transaction type. As a generic SEC regulatory report, it falls under Regulatory Filings (RNS).
2026-06-05 English
S-3
Regulatory Filings Classification · 75% confidence The document is an SEC Form S-3 registration statement and prospectus detailing the resale of up to 11,587,000 shares of common stock by selling stockholders. It is not an annual or quarterly report, earnings release, proxy statement, or management presentation, but a regulatory filing under the Securities Act of 1933. As there is no specific category for SEC registration statements in the taxonomy, it falls under the General Regulatory Filings (RNS) fallback category.
2026-05-29 English
10-Q - Climb Bio, Inc. (0001768446) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
8-K - Climb Bio, Inc. (0001768446) (Filer)
Earnings Release Classification · 89% confidence The document is a Form 8-K Current Report filed under Item 2.02 “Results of Operations and Financial Condition,” which furnishes a press release announcing quarterly financial results (for the quarter ended March 31, 2026). This is the standard mechanism for an earnings release via an SEC Form 8-K. It does not contain full financial statements (so not an interim report), but serves as the initial announcement of quarterly results. Therefore, it fits the Earnings Release category. Q1 2026
2026-05-07 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.